Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey - Takeaways - MDSpire

Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey

  • By

  • Lisa S. Hönikl

  • Sebastian Lange

  • Bernhard Meyer

  • Stephanie E. Combs

  • Alisa M. Lörsch

  • Anna Lena Illert

  • Arthur Wagner

  • Friederike Schmidt-Graf

  • March 31, 2026

  • 0 min

Share

  • 1

    Molecular Tumor Boards (MTBs) are crucial for guiding personalized treatment decisions in neuro-oncology despite challenges in precision medicine.

  • 2

    A nationwide survey in Germany revealed broad implementation of MTBs but significant variability in structure and practices across centers.

  • 3

    Key barriers to effective MTB integration include lack of reimbursement for off-label therapies and insufficient standardization.

  • 4

    Recent developments, such as the INDIGO trial and EANO guidelines, aim to enhance molecular profiling and standardize MTB practices.

  • 5

    The follow-up survey in 2025 assessed changes in MTB integration and identified ongoing gaps in access to targeted therapies and clinical workflows.

Original Source(s)

Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey

  • by Lisa S. Hönikl, Sebastian Lange, Bernhard Meyer, Stephanie E. Combs, Alisa M. Lörsch, Anna Lena Illert, Arthur Wagner, Friederike Schmidt-Graf

  • March 31, 2026

Related Content

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

High-grade astrocytoma with piloid features: a case report of comprehensive management